Fisons and Porton link up
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.FISONS, the pharmaceutical group, said yesterday that it had linked up with Porton Products, the specialist drug company, to develop and market Fisons' Dopacard product worldwide, writes Gail Counsell.
Dopacard, which already has product licences in the UK, Ireland, the Netherlands, Sweden, Switzerland and New Zealand, is used in connection with heart failure associated with cardiac surgery.
Porton is to seek product licences for Dopacard in countries where they have not yet been agreed, and will work on alternative uses for the drug.
This week Fisons revealed it had formed a strategic alliance with Allergan in the US for the promotion and marketing of its Opticrom eye solution. Fisons has said it wants to have more flexible marketing arrangements for its products.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments